Table 3.
Analyses of SCLC pooled hazard ratios for OS outcomes by subgroup.
| Variables | Study, N(%) | Number of patients(N) | Pooled HR (95%CI) | p value for interaction | ||
|---|---|---|---|---|---|---|
| LMs | non-LMs | LMs | non-LMs | |||
| Overall | 4 (100) | 869 | 1389 | 0.94 (0.73,1.23) | 0.79 (0.69,0.90) | 0.036 |
| Line of therapy | ||||||
| First-line | 2 (50) | 339 | 517 | 0.75 (0.59,0.95) | 0.79 (0.65,0.97) | 0.7252 |
| Second- or later-line | 2 (50) | 530 | 872 | 1.09 (0.92,1.30) | 0.79 (0.68,0.91) | 0.0044 |
SCLC, small cell lung cancer; LMs, liver metastases; OS, overall survival; HR, hazard ratio; CI, confidence interval. Bold values indicate statisticallysignificant findings with p<0.05.